

Indolent Lymphoma Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/I974D5B9A999EN.html>

Date: March 2022

Pages: 66

Price: US\$ 3,250.00 (Single User License)

ID: I974D5B9A999EN

Abstracts

This report contains market size and forecasts of Indolent Lymphoma Treatment in Global, including the following market information:

Global Indolent Lymphoma Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Indolent Lymphoma Treatment market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

BI-836826 Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Indolent Lymphoma Treatment include Altor BioScience Corporation, Amgen Inc., Astellas Pharma Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company and F. Hoffmann-La Roche Ltd., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Indolent Lymphoma Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Indolent Lymphoma Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Indolent Lymphoma Treatment Market Segment Percentages, by Type, 2021 (%)

BI-836826

ALT-803

BMS-986016

CC-122

Others

Global Indolent Lymphoma Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Indolent Lymphoma Treatment Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Others

Global Indolent Lymphoma Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Indolent Lymphoma Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Indolent Lymphoma Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Indolent Lymphoma Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Altor BioScience Corporation

Amgen Inc.

Astellas Pharma Inc.

Bayer AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Juno Therapeutics Inc.

MedImmune, LLC

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Indolent Lymphoma Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Indolent Lymphoma Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL INDOLENT LYMPHOMA TREATMENT OVERALL MARKET SIZE

- 2.1 Global Indolent Lymphoma Treatment Market Size: 2021 VS 2028
- 2.2 Global Indolent Lymphoma Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Indolent Lymphoma Treatment Players in Global Market
- 3.2 Top Global Indolent Lymphoma Treatment Companies Ranked by Revenue
- 3.3 Global Indolent Lymphoma Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Indolent Lymphoma Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Indolent Lymphoma Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Indolent Lymphoma Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Indolent Lymphoma Treatment Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Indolent Lymphoma Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Indolent Lymphoma Treatment Market Size Markets, 2021 & 2028

4.1.2 BI-836826

4.1.3 ALT-803

4.1.4 BMS-986016

4.1.5 CC-122

4.1.6 Others

4.2 By Type - Global Indolent Lymphoma Treatment Revenue & Forecasts

4.2.1 By Type - Global Indolent Lymphoma Treatment Revenue, 2017-2022

4.2.2 By Type - Global Indolent Lymphoma Treatment Revenue, 2023-2028

4.2.3 By Type - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Indolent Lymphoma Treatment Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.1.4 Others

5.2 By Application - Global Indolent Lymphoma Treatment Revenue & Forecasts

5.2.1 By Application - Global Indolent Lymphoma Treatment Revenue, 2017-2022

5.2.2 By Application - Global Indolent Lymphoma Treatment Revenue, 2023-2028

5.2.3 By Application - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Indolent Lymphoma Treatment Market Size, 2021 & 2028

6.2 By Region - Global Indolent Lymphoma Treatment Revenue & Forecasts

6.2.1 By Region - Global Indolent Lymphoma Treatment Revenue, 2017-2022

6.2.2 By Region - Global Indolent Lymphoma Treatment Revenue, 2023-2028

6.2.3 By Region - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Indolent Lymphoma Treatment Revenue, 2017-2028

6.3.2 US Indolent Lymphoma Treatment Market Size, 2017-2028

6.3.3 Canada Indolent Lymphoma Treatment Market Size, 2017-2028

6.3.4 Mexico Indolent Lymphoma Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Indolent Lymphoma Treatment Revenue, 2017-2028

6.4.2 Germany Indolent Lymphoma Treatment Market Size, 2017-2028

6.4.3 France Indolent Lymphoma Treatment Market Size, 2017-2028

6.4.4 U.K. Indolent Lymphoma Treatment Market Size, 2017-2028

6.4.5 Italy Indolent Lymphoma Treatment Market Size, 2017-2028

6.4.6 Russia Indolent Lymphoma Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Indolent Lymphoma Treatment Market Size, 2017-2028

6.4.8 Benelux Indolent Lymphoma Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Indolent Lymphoma Treatment Revenue, 2017-2028

6.5.2 China Indolent Lymphoma Treatment Market Size, 2017-2028

6.5.3 Japan Indolent Lymphoma Treatment Market Size, 2017-2028

6.5.4 South Korea Indolent Lymphoma Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Indolent Lymphoma Treatment Market Size, 2017-2028

6.5.6 India Indolent Lymphoma Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Indolent Lymphoma Treatment Revenue, 2017-2028

6.6.2 Brazil Indolent Lymphoma Treatment Market Size, 2017-2028

6.6.3 Argentina Indolent Lymphoma Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Indolent Lymphoma Treatment Revenue, 2017-2028

6.7.2 Turkey Indolent Lymphoma Treatment Market Size, 2017-2028

6.7.3 Israel Indolent Lymphoma Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Indolent Lymphoma Treatment Market Size, 2017-2028

6.7.5 UAE Indolent Lymphoma Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Altor BioScience Corporation

7.1.1 Altor BioScience Corporation Corporate Summary

7.1.2 Altor BioScience Corporation Business Overview

7.1.3 Altor BioScience Corporation Indolent Lymphoma Treatment Major Product Offerings

7.1.4 Altor BioScience Corporation Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)

- 7.1.5 Altor BioScience Corporation Key News
- 7.2 Amgen Inc.
 - 7.2.1 Amgen Inc. Corporate Summary
 - 7.2.2 Amgen Inc. Business Overview
 - 7.2.3 Amgen Inc. Indolent Lymphoma Treatment Major Product Offerings
 - 7.2.4 Amgen Inc. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
 - 7.2.5 Amgen Inc. Key News
- 7.3 Astellas Pharma Inc.
 - 7.3.1 Astellas Pharma Inc. Corporate Summary
 - 7.3.2 Astellas Pharma Inc. Business Overview
 - 7.3.3 Astellas Pharma Inc. Indolent Lymphoma Treatment Major Product Offerings
 - 7.3.4 Astellas Pharma Inc. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
 - 7.3.5 Astellas Pharma Inc. Key News
- 7.4 Bayer AG
 - 7.4.1 Bayer AG Corporate Summary
 - 7.4.2 Bayer AG Business Overview
 - 7.4.3 Bayer AG Indolent Lymphoma Treatment Major Product Offerings
 - 7.4.4 Bayer AG Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
 - 7.4.5 Bayer AG Key News
- 7.5 Boehringer Ingelheim GmbH
 - 7.5.1 Boehringer Ingelheim GmbH Corporate Summary
 - 7.5.2 Boehringer Ingelheim GmbH Business Overview
 - 7.5.3 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Major Product Offerings
 - 7.5.4 Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
 - 7.5.5 Boehringer Ingelheim GmbH Key News
- 7.6 Bristol-Myers Squibb Company
 - 7.6.1 Bristol-Myers Squibb Company Corporate Summary
 - 7.6.2 Bristol-Myers Squibb Company Business Overview
 - 7.6.3 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Major Product Offerings
 - 7.6.4 Bristol-Myers Squibb Company Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
 - 7.6.5 Bristol-Myers Squibb Company Key News
- 7.7 Celgene Corporation
 - 7.7.1 Celgene Corporation Corporate Summary

- 7.7.2 Celgene Corporation Business Overview
- 7.7.3 Celgene Corporation Indolent Lymphoma Treatment Major Product Offerings
- 7.7.4 Celgene Corporation Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
- 7.7.5 Celgene Corporation Key News
- 7.8 Eli Lilly and Company
 - 7.8.1 Eli Lilly and Company Corporate Summary
 - 7.8.2 Eli Lilly and Company Business Overview
 - 7.8.3 Eli Lilly and Company Indolent Lymphoma Treatment Major Product Offerings
 - 7.8.4 Eli Lilly and Company Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
 - 7.8.5 Eli Lilly and Company Key News
- 7.9 F. Hoffmann-La Roche Ltd.
 - 7.9.1 F. Hoffmann-La Roche Ltd. Corporate Summary
 - 7.9.2 F. Hoffmann-La Roche Ltd. Business Overview
 - 7.9.3 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Major Product Offerings
 - 7.9.4 F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
 - 7.9.5 F. Hoffmann-La Roche Ltd. Key News
- 7.10 Gilead Sciences, Inc.
 - 7.10.1 Gilead Sciences, Inc. Corporate Summary
 - 7.10.2 Gilead Sciences, Inc. Business Overview
 - 7.10.3 Gilead Sciences, Inc. Indolent Lymphoma Treatment Major Product Offerings
 - 7.10.4 Gilead Sciences, Inc. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
 - 7.10.5 Gilead Sciences, Inc. Key News
- 7.11 Incyte Corporation
 - 7.11.1 Incyte Corporation Corporate Summary
 - 7.11.2 Incyte Corporation Business Overview
 - 7.11.3 Incyte Corporation Indolent Lymphoma Treatment Major Product Offerings
 - 7.11.4 Incyte Corporation Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)
 - 7.11.5 Incyte Corporation Key News
- 7.12 Infinity Pharmaceuticals, Inc.
 - 7.12.1 Infinity Pharmaceuticals, Inc. Corporate Summary
 - 7.12.2 Infinity Pharmaceuticals, Inc. Business Overview
 - 7.12.3 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Major Product Offerings

7.12.4 Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)

7.12.5 Infinity Pharmaceuticals, Inc. Key News

7.13 Juno Therapeutics Inc.

7.13.1 Juno Therapeutics Inc. Corporate Summary

7.13.2 Juno Therapeutics Inc. Business Overview

7.13.3 Juno Therapeutics Inc. Indolent Lymphoma Treatment Major Product Offerings

7.13.4 Juno Therapeutics Inc. Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)

7.13.5 Juno Therapeutics Inc. Key News

7.14 MedImmune, LLC

7.14.1 MedImmune, LLC Corporate Summary

7.14.2 MedImmune, LLC Business Overview

7.14.3 MedImmune, LLC Indolent Lymphoma Treatment Major Product Offerings

7.14.4 MedImmune, LLC Indolent Lymphoma Treatment Revenue in Global Market (2017-2022)

7.14.5 MedImmune, LLC Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Indolent Lymphoma Treatment Market Opportunities & Trends in Global Market

Table 2. Indolent Lymphoma Treatment Market Drivers in Global Market

Table 3. Indolent Lymphoma Treatment Market Restraints in Global Market

Table 4. Key Players of Indolent Lymphoma Treatment in Global Market

Table 5. Top Indolent Lymphoma Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Indolent Lymphoma Treatment Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Indolent Lymphoma Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Indolent Lymphoma Treatment Product Type

Table 9. List of Global Tier 1 Indolent Lymphoma Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Indolent Lymphoma Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Indolent Lymphoma Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Indolent Lymphoma Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Indolent Lymphoma Treatment Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Indolent Lymphoma Treatment Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Indolent Lymphoma Treatment Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Indolent Lymphoma Treatment Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Altor BioScience Corporation Corporate Summary

Table 31. Altor BioScience Corporation Indolent Lymphoma Treatment Product Offerings

Table 32. Altor BioScience Corporation Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. Amgen Inc. Corporate Summary

Table 34. Amgen Inc. Indolent Lymphoma Treatment Product Offerings

Table 35. Amgen Inc. Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Astellas Pharma Inc. Corporate Summary

Table 37. Astellas Pharma Inc. Indolent Lymphoma Treatment Product Offerings

Table 38. Astellas Pharma Inc. Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Bayer AG Corporate Summary

Table 40. Bayer AG Indolent Lymphoma Treatment Product Offerings

Table 41. Bayer AG Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Boehringer Ingelheim GmbH Corporate Summary

Table 43. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Product Offerings

Table 44. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Bristol-Myers Squibb Company Corporate Summary

Table 46. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Product Offerings

Table 47. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. Celgene Corporation Corporate Summary

Table 49. Celgene Corporation Indolent Lymphoma Treatment Product Offerings

Table 50. Celgene Corporation Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Eli Lilly and Company Corporate Summary

Table 52. Eli Lilly and Company Indolent Lymphoma Treatment Product Offerings

Table 53. Eli Lilly and Company Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. F. Hoffmann-La Roche Ltd. Corporate Summary

Table 55. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Product Offerings

Table 56. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 57. Gilead Sciences, Inc. Corporate Summary

Table 58. Gilead Sciences, Inc. Indolent Lymphoma Treatment Product Offerings

Table 59. Gilead Sciences, Inc. Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 60. Incyte Corporation Corporate Summary

Table 61. Incyte Corporation Indolent Lymphoma Treatment Product Offerings

Table 62. Incyte Corporation Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 63. Infinity Pharmaceuticals, Inc. Corporate Summary

Table 64. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Product Offerings

Table 65. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 66. Juno Therapeutics Inc. Corporate Summary

Table 67. Juno Therapeutics Inc. Indolent Lymphoma Treatment Product Offerings

Table 68. Juno Therapeutics Inc. Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

Table 69. MedImmune, LLC Corporate Summary

Table 70. MedImmune, LLC Indolent Lymphoma Treatment Product Offerings

Table 71. MedImmune, LLC Indolent Lymphoma Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Indolent Lymphoma Treatment Segment by Type in 2021
- Figure 2. Indolent Lymphoma Treatment Segment by Application in 2021
- Figure 3. Global Indolent Lymphoma Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Indolent Lymphoma Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Indolent Lymphoma Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Indolent Lymphoma Treatment Revenue in 2021
- Figure 8. By Type - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
- Figure 12. US Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Indolent Lymphoma Treatment Revenue Market Share, 2017-2028
- Figure 24. China Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Indolent Lymphoma Treatment Revenue, (US\$, Mn),

2017-2028

Figure 28. India Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Indolent Lymphoma Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Indolent Lymphoma Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Indolent Lymphoma Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Altor BioScience Corporation Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Amgen Inc. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Astellas Pharma Inc. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Bayer AG Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Boehringer Ingelheim GmbH Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Bristol-Myers Squibb Company Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Celgene Corporation Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Eli Lilly and Company Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. F. Hoffmann-La Roche Ltd. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Gilead Sciences, Inc. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Incyte Corporation Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Infinity Pharmaceuticals, Inc. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Juno Therapeutics Inc. Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. MedImmune, LLC Indolent Lymphoma Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Indolent Lymphoma Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/I974D5B9A999EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I974D5B9A999EN.html>